Faricimab for type 3 wet age-related macular degeneration
Part of Eyes & vision clinical trials.
This study tests a medicine called faricimab, which is injected into the eye to treat a certain type of wet age-related macular degeneration (type 3). The goal is to see if it can safely improve vision over the long term when doses are adjusted based on how the eye responds.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are 50 years or older
- You have been diagnosed with type 3 macular neovascularization (a specific form of wet age-related macular degeneration)
- You have never received treatment for this condition before
- Your vision in the study eye is at least 20/320 (24 letters on an eye chart)
- You have not had a stroke or heart attack in the last 6 months
- You are not pregnant or planning to become pregnant during the study
- You do not have uncontrolled high blood pressure (above 180/100 mmHg)
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study tests if faricimab, an injectable eye medication, can improve vision in people with a newly diagnosed form of wet age-related macular degeneration (AMD). It is for patients who have not yet received treatment for this condition.
This study tests a personalized treatment plan using an investigational drug called faricimab for people who have a specific type of wet age-related macular degeneration known as polypoidal choroidal vasculopathy. The goal is to see if adjusting the time between injections based on your individual needs can safely dry up fluid in the retina and improve vision.
This study observes how a drug called faricimab works in treating wet AMD (a condition affecting central vision in older adults). You would receive four initial injections into your eye, then additional injections as needed based on your response.
This trial tests a new injection called faricimab for people with wet age-related macular degeneration (AMD) that hasn't improved enough with standard anti-VEGF shots. The goal is to see if faricimab can reduce retinal fluid and improve vision in patients who still have fluid despite many previous treatments.
This trial tests if faricimab eye injections given every 3 months can keep wet age-related macular degeneration under control. It is for people with a new or returning active blood vessel growth in the center of the macula.
This trial tests a new drug called Faricimab for people with a specific type of wet age-related macular degeneration (AMD) that has a buildup of material beneath the retina. The goal is to see if Faricimab can help clear this material and improve vision.
Hear when a new Age-related Macular Degeneration (ARMD) trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.